A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) (NCT07500090)
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) Followed by an Open-label Extension
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in adult participants (ages ≥18 years) with idiopathic hypersomnia (IH).
Who can join: Review the eligibility criteria below.
Location: Sleep Disorders Center of Alabama — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (40 Sites)
Showing the first 25 of 40 sites.
- Sleep Disorders Center of Alabama — Birmingham, Alabama
- Phoenix Medical Group LLC — Peoria, Arizona
- Stanford Center for Sleep Medicine — Redwood City, California
- Trial Site Solutions — San Ramon, California
- Santa Monica Clinical Trials — Santa Monica, California
- Alpine Clinical Research Center, Inc. — Boulder, Colorado
- Delta Waves LLC — Colorado Springs, Colorado
- PharmDev Research Institute, LLC — Miami, Florida
- Central Florida Pediatric Sleep Disorders Institute (Florida Pediatric Research Institute, LLC) — Winter Park, Florida
- NeuroTrials Research Inc. — Atlanta, Georgia
- Sleep Practitioners, LLC — Macon, Georgia
- Southeast Lung Associates Research — Rincon, Georgia
- Clinical Research Institute Stockbridge — Stockbridge, Georgia
- Fort Wayne Neurological Center — Fort Wayne, Indiana
- Revive Research Institute — Southfield, Michigan
- Clinical Neuropsychology Services — Sterling Heights, Michigan
- St. Luke's Hospital, Sleep Medicine and Research Center — Chesterfield, Missouri
- Clinical Research of Gastonia — Gastonia, North Carolina
- Stern Research Partners, LLC — Huntersville, North Carolina
- David Kudrow, MD — Morrisville, North Carolina
- Neuroscience Research Center, LLC — Canton, Ohio
- Intrepid Research — Cincinnati, Ohio
- Neurology Care — Ardmore, Oklahoma
- Abington Neurological Associates — Abington, Pennsylvania
- Suburban Research Associates — West Chester, Pennsylvania
📞 Contact the Study Coordinator
Phone: (205) 599-1020
Email: jwright@sleepalabama.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Idiopathic Hypersomnia
- A Study of TAK-360 in Adults With Idiopathic Hypersomnia — Redwood City, California
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia — Cullman, Alabama
- A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia — Brandon, Florida
- Low Sodium Oxybate in Patients With Idiopathic Hypersomnia — Phoenix, Arizona
Explore by condition: All Idiopathic Hypersomnia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.